ABVC Biopharma announced that on October 20, 2022, it received a Notice of Allowance for ABV-1504 from the US Patent and Trademark Office. The patent, entitled "Polygala Extract for the Treatment of Major Depressive Disorder," outlines a method for treating major depressive disorder by oral administration of a composition, ABV-1504, containing Radix Polygalae. The polygala extract, designated PDC-1421, is the key active ingredient in ABV-1504 which was orally administered to healthy volunteers and proved to be safe and well-tolerated for a daily dose from 380 mg to 3800 mg. The study indicated that the drug can be administered chronically over at least 25 days with the daily dose administered once per day, twice per day, or three times per day, wherein each dose contains from 380 mg to 760 mg of the botanical extraction. In addition to the United States, the patent was also filed in China, Taiwan and under the Patent Cooperation Treaty. The PCT patent application was published on January 27, 2022, and subsequently was filed in Japan, Australia and with the European Patent Office.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ABVC:
- ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)
- Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma’s Medication for Treating Depression in Cancer Patients
- ABVC BioPharma announces CSMC joins Phase I study of ABV-1601
- ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia
- ABVC BioPharma (NASDAQ:ABVC) in Focus on ADHD Trial Update